Last edition
News about
WACKER & CordenPharma Enter Pandemic Readiness State for Germany
WACKER and CordenPharma have officially entered the pandemic readiness state as of June 1, 2024.
ANI Pharmaceuticals to Acquire Alimera to Expand Rare Disease
ANI Pharmaceuticals, Inc. has announced that ANI will acquire Alimera for USD 5.50 per share in cash at closing and one non-tradable contingent value right (CVR) representing the right to receive up to USD 0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027.
Sun Pharma Announces Complete Acquisition of Taro
Sun Pharmaceutical Industries Ltd. has completed the merger of Taro Pharmaceutical Industries Ltd. with its subsidiary.
Biocon Biologics Gets EMA Approval for Bevacizumab and its New mAbs Facility in India
Biocon Biologics Ltd. has received approval from the European Medicines Agency (EMA) to manufacture biosimilar Bevacizumab at its new, world-class, multi-product monoclonal antibodies (mAbs) drug substance facility in Bengaluru.
Sun Pharma Signs Non-Exclusive Patent Licensing Deal with Takeda for Vonoprazan
Sun Pharma has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company Ltd. to commercialise Vonoprazan tablets 10 mg, 20 mg in India under the brand name Voltapraz.
Lupin Gets EIR from US FDA for its Somerset Manufacturing Facility
Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its manufacturing facility in Somerset.
argenx Secures FDA Approval for VYVGART Hytrulo Co-Formulated with ENHANZE
Halozyme Therapeutics has announced that argenx has received US Food and Drug Administration (FDA) approval for VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) co-formulated with ENHANZE, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of adults with chronic inflammatory demyelinating polyneuropathy.
Bora to Acquire Emergent Sterile Manufacturing Facility in Maryland
Bora Pharmaceuticals has signed an agreement for Emergent BioSolutions' sterile manufacturing facility in Baltimore-Camden, Maryland as part of a major commercial expansion for the company.
Abzena and Argonaut to Offer End-to-End Drug Development Support for Biopharma Companies
Abzena has inked a strategic partnership with Argonaut Manufacturing Services, Inc. to provide a fully integrated drug substance and drug product manufacturing solution for biopharmaceutical organizations.
Johnson & Johnson Submits Application to US FDA Seeking Approval of TREMFYA
Johnson & Johnson has submitted a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) seeking approval of TREMFYA (guselkumab) for the treatment of adults with moderately to severely active Crohn's disease.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy